This test complements the KRAS/BRAF Mutation Analysis Test and is indicated in the setting of metastatic colorectal cancer whereby the first round of screening for mutations in KRAS oncogene exons 2, 3 and 4 is already negative, i.e. to look for specific mutations in exons 2, 3 and 4 of the NRAS gene. The presence of certain NRAS mutations correlates with a lack of response to certain EGFR inhibitor cancer therapies in metastatic colorectal cancer patients.
Paraffin embedded tissue block sent to the Histopathology Section. Alternatively, unstained slides can be sent to the Histopathology Section. At least 8 sections of 8 µm thickness, or 12 sections of 5 µm thickness for smaller biopsies should be sent together with one H&E slide, 4 µm thick with a coverslip as a reference slide. Tumour content must be indicated and must be at least 30%.
Direct PCR sequencing (In-house test)
Specific mutations detected, No mutations Detected or Inconclusive
Subscribe to our mailing list to get the updates to your email inbox...